Vascular BioSciences


Vascular BioSciences is a diversified biomedical company dedicated to developing products that enhance and prolong human life. They focus on vascular-based diseases, providing solutions such as interventional catheters for biopsies, molecular diagnostics, and targeted therapies for serious diseases. Their mission is to improve disease outcomes and develop innovative medical solutions.

Industries

biopharma
biotechnology
medical-device
product-research

Nr. of Employees

small (1-50)

Vascular BioSciences


Patents

Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same

US-11642391-B2

View Details

Orally active, cell-penetrating homing peptide and methods using same

US-11524077-B2

View Details

Car peptide for homing, diagnosis and targeted therapy for pulmonary and fibrotic disorders

US-10039838-B2

View Details

Orally active, cell-penetrating homing peptide and methods of using same

US-9655973-B2

View Details

Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis

US-9603890-B2

View Details

Methods of novel therapeutic candidate identification through gene expression analysis in vascular related diseases

US-9499816-B2

View Details
View All Patents

Products

Endoarterial biopsy catheter and procedural kits

A percutaneous interventional catheter system and single-use kit components designed to obtain arterial tissue samples suitable for histology, culture and molecular assays.

Peptide-targeted liposomal therapeutic platform (pipeline)

Peptide-modified liposomal formulations developed to preferentially target diseased vascular tissue; pipeline includes inhalable formulations encapsulating combination small molecules for pulmonary arterial hypertension.

Vascular diagnostic profiling product/platform

An integrated diagnostic approach combining arterial biopsy sampling with multi-omic laboratory analyses to generate a comprehensive vascular disease profile for individualized care.

Inhalable peptide-modified liposomal combination therapy (development-stage)

Pipeline formulation combining multiple small-molecule agents in peptide-modified liposomes for inhalation delivery to the pulmonary vasculature; preclinical data report hemodynamic and structural improvements in pulmonary hypertension models.


Services

Laboratory services that perform histological, gene expression and proteomic analyses of arterial biopsy specimens to produce integrated vascular disease profiles for diagnostic and therapeutic decision support.

Expertise Areas

  • Interventional device development for arterial access and minimally invasive tissue sampling
  • Vascular molecular diagnostics and multi-omic profiling
  • Targeted therapeutics development using disease-homing peptides
  • Inhalable liposomal drug formulation development for pulmonary delivery
  • Show More (6)

Key Technologies

  • Endoarterial biopsy catheters and percutaneous sampling techniques
  • Disease-homing peptides for tissue-targeted delivery
  • Liposomal drug carriers and inhalable lipid formulations
  • Combination drug encapsulation in nanocarriers
  • Show More (6)

News & Updates

Vascular BioSciences Will Present Results of “CAR Peptide Targeted Liposomes Loaded with an Admixture of Fasudil and DETA Nonoate for the Treatment of PAH” at the American Thoracic Society International Conference in San Diego, California on May 22, 2024

Vascular BioSciences Announces Publication of “Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate Ameliorates Various Pathologies of Pulmonary Arterial Hypertension”

Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal

Vascular BioSciences Announces Publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the Current Issue of The Open Respiratory Medicine Journal

Vascular BioSciences Receives $2.7M STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California

Intratracheally Administered Peptide-Modified Lipid Admixture Containing Fasudil and/or DETA NONOate for the Treatment of PAH

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.